**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: February 12, 1990
* Sex: Male
* Admission Date: March 10, 2023
* Discharge Date: March 15, 2023
* Hospital Number: 123456

**Clinical Summary:**

John Doe, a 33-year-old male, was admitted to the infectious diseases unit on March 10, 2023, with symptoms of influenza-like illness, including fever, cough, and fatigue. He presented with a temperature of 102.5°F (39.1°C), tachycardia of 110 beats per minute, and tachypnea of 24 breaths per minute. On physical examination, he had bilateral wheezing and rhonchi.

**Diagnostic Work-Up:**

* Rapid antigen test (RAT) performed on March 10, 2023, was negative.
* Reverse Transcription-Polymerase Chain Reaction (RT-PCR) test performed on March 11, 2023, confirmed influenza A (H3N2) infection.
* Chest x-ray performed on March 12, 2023, showed interstitial infiltrates consistent with primary influenza pneumonia.

**Treatment and Management:**

* The patient was placed on oxygen therapy with a nasal cannula at 2 liters per minute.
* He received antiviral therapy with Oseltamivir 75 mg orally twice a day, starting on March 11, 2023.
* Symptomatic treatment included rest, hydration, and antipyretics (acetaminophen 325 mg every 4 hours as needed).
* Aspirin was avoided due to the patient's age and the risk of Reye's syndrome.
* Pulse oximetry and chest x-ray were repeated on March 14, 2023, which showed continued improvement in oxygen saturation and resolution of interstitial infiltrates.

**Laboratory Results:**

* Complete Blood Count (CBC) performed on March 10, 2023, showed a white blood cell count of 12,000 cells per microliter, hemoglobin of 13.5 grams per deciliter, and platelet count of 150,000 cells per microliter.
* Blood cultures performed on March 10, 2023, were negative for bacterial pathogens.
* Influenza viral RNA was detected in nasopharyngeal swabs on March 11, 2023.

**Discharge Instructions:**

* The patient was advised to continue rest and hydration at home.
* He was instructed to complete the full course of Oseltamivir therapy, which was scheduled to be discontinued on March 16, 2023.
* The patient was cautioned against returning to work or school until the fever had resolved for at least 24 hours.
* He was advised to seek medical attention immediately if symptoms worsened, or if he developed shortness of breath, chest pain, or difficulty breathing.

**Follow-Up:**

* The patient was scheduled for a follow-up appointment with the primary care physician on March 20, 2023, to assess for any residual symptoms or complications.

**Summary:**

John Doe was admitted to the infectious diseases unit with influenza-like illness and was diagnosed with influenza A (H3N2) infection. He received antiviral therapy with Oseltamivir and symptomatic treatment, which resulted in improvement in his symptoms and resolution of interstitial infiltrates on chest x-ray. He was discharged with instructions for continued rest, hydration, and antiviral therapy at home.